Recro Pharma Reports First Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to Recro Pharma Reports First Quarter 2019 Financial Results

Recro Pharma (REPH) Tops Q1 EPS by 96c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus

May 10, 2019 7:09 AM EDT

Recro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.10), $0.96 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $25.07 million versus the consensus estimate of $20.51 million.

Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. Growth of the Gainesville CDMO continues to accelerate as a result of strong demand... More